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Analysis of the effects of a range of concentrations of the antihyperlipoproteinemia drug, bezafibrate, on 
the oxygen dissociation curve of dilute hemoglobin solutions indicates a 4: 1 binding stoichiometry with 
a site binding constant of 434 mol-’ for deoxyhemoglobin. Analysis of the combined effects of a range 
of bezafibrate and 2,3-diphosphoglycerate (DPG) concentrations indicates that 2 of the 4 bezafibrate sites 
are in the vicinity of the DPG binding site, and competitive with DPG binding, and 2 of the sites are remote 
from the DPG binding site. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
A recent publication [I] described the right- 
shifting effect of an antihyperlipoproteinemia drug 
in current use, bezafibrate, on the oxygen dissocia- 
tion curve of hemo~obin. Unlike most other right- 
shifting agents which are highly charged anions, 
this compound was able to cross the red cell mem- 
brane and gave right-shifts in whole blood as well 
as on hemoglobin solution. The potential clinical 
benefits for such a compound were discussed [l]. 
A more detailed analysis of the effects of 
bezafibrate on the oxygen dissociation curve of 
dilute hemoglobin solutions, both alone and in 
combination with the natural effector, DPG [2], is 
presented here. It is shown that bezafibrate binds 
at multiple sites on the hemoglobin tetramer with 
a relatively weak association constant (434 mol-‘) 
and it is therefore doubtful whether the binding is 
sufficiently specific for hemoglobin compared to 
other proteins for the compound to be useful as a 
right-shifting agent in vivo. 
Human hemoglobin solutions of low phosphate 
content were prepared as in [3] and stored as 2-cm3 
aliquots at -20°C. Bezafibrate was a gift from 
Boehringer and DPG was purchased as the Tris 
salt from Calbiochem. Both compounds were used 
without further purification. 
~bbrevjations; DPG, 2,3-diphospho~ycerate; IHP, 
myo-inositof hexaphosphate; bezafibrate, 2-[4-(2-p- 
chlorobenzamidoethyl)phenoxyl]3-methylpropionate 
Oxygen dissociation curve measurements of 
dilute hemoglobin solutions (23 PM on a tetramer 
basis, 5.4 ml solution) were carried out at 37°C us- 
ing a commerci~ly available automatic apparatus 
(Hemox-Analyzer, TCS Medical Products Divi- 
sion, Southampton, PA). Hemoglobin solutions 
containing the required concentrations of com- 
pounds plus 35 mM KC1 in 100 mM Hepes buffer 
adjusted to pH 7.4 were prepared in the optical cell 
(path length 15 mm). They were equilibrated in air 
for 10 min before bubbling nitrogen (British Ox- 
ygen Company ‘white spot’) through the stirred 
solution to deoxygenate it, which typically re- 
quired about 30 min. Twentypl of a 1.5% solution 
of silicone emulsion (diluted 1 in 20 from a 
stronger solution purchased from BDH) was also 
added to prevent frothing. The dissociation curves 
were measured as continuous curves on an X-Y 
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plotter and in digital form (- 150 points/curve) us- 
ing an A-D converter (Interactive Structures Inc.) 
and an Apple IIe microcomputer. For subsequent 
data analysis 10 points per curve were selected at 
appropriate intervals along the saturation axis and 
theoretical models were fitted to the data using a 
standard non-linear iterative procedure as in 141. 
Pm values (median oxygen pressure, the pressure at 
which the concentrations of deoxy- and ox- 
yhemoglobin are equal) were calculated from the 
results of fitting the Adair equation to each data 
set [5]. Replicate determinations gave an 
associated error in P,,, of f 2% (standard devia- 
tion/mean). 
3. RESULTS 
The effect of a range of bezafibrate concentra- 
tions on the oxygen dissociation curve of dilute 
hemoglobin solution is shown in fig.1. The com- 
pound produces large right-shifts at high concen- 
trations comparable to the shifts obtained with the 
most potent allosteric effector known at present, 
IHP [4]. However, bezafibrate differs from IHP in 
two important respects; much higher concentra- 
tions are necessary to produce similar effects and 
the range of effect for bezafibrate occurs over a 
narrower concentration range compared with 
other effecters such as IHP or DPG. Fig.2 shows 
50 100 
PO, (mm 4) 
Fig. 1. Effect of a range of bezafibrate concentrations on 
the oxygen dissociation curve of dilute (23 PM) 
hemoglobin solutions; 100 mM Hepes buffer (pH 7.4), 
35 mM KCI, T = 37°C. Bezafibrate concentration from 
where d is the free compound concentration and 
KD and KO are the association constants for bind- 
ing to deoxy- and oxyhemoglobin, respectively (for 
n > 1 the individual sites are assigned the same site 
association constants and it is assumed that n is the 
same for oxy- and deoxyhemoglobin). For beza- 
fibrate the lowest concentration used (1 mM) was 
more than 40 times the hemoglobin concentration 
(0.023 mM) so the total compound added was 
equated with the free concentration. Eq.1 was fit- 
ted non-linearly for values of n fixed at I, 2 and 4 
or allowed to float and the results are shown in 
table 1. The most satisfactory fit to the data is 
clearly obtained for n = 4, and the corresponding 
values for Kn and KO are 434 + 14 mol-’ and 19.0 
I 2.5 mol-‘, respectively. When the value of n 
was allowed to vary it was found to be not signifi- 
cantly different from 4. 
left to right: 0, 1, 2, 3.5, 5, 7, 10, 15, 20, 30 mM. Table 2 shows the effect of a range of DPG and 
1.8 
Fig.2. Plot of log P,,, vs log concentration for DPG and 
bezafibrate, conditions as for fig.1: (0) DPG; (0) 
bezafibrate. The lines are the best-fit curves from fitting 
eq.1 to the data with: (-) n = 1, (---) n = 2, 
(-----) n = 4 where n is the number of binding sites. 
plots of log P,,, against log concentration for DPG 
and bezafibrate and illustrates the steeper slope of 
the bezafibrate curve, suggesting multiple binding 
sites and cooperativity in binding for this 
compound. 
For a compound binding at n equivalent sites on 
the hemoglobin tetramer eq.1 holds [5]: 
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Table 1 
Results of fitting eq.1 with various binding 
stoichiometries to log Pm data for bezafibrate 
Binding site 
number (n) 
KD 
(mol- ‘) 
Ko 
(mol-‘) 
Sum of 
squares 
1 25500 0 1.0380 
(13200) 
2 1780 0 0.1680 
(21) 
4 434 19.0 0.0059 
(14) (2.5) 
4.73 364 29.4 0.0055 
(1.43) (108) (19.2) 
Eq.1 was fitted to the data illustrated in fig.2 for 
bezafibrate with the binding stoichiometry fixed at the 
values indicated or allowed to float. For n = 1 and 2 the 
value of KO was not significantly different from zero. 
The sum of squares is the sum of the squares of residuals 
between observed and calculated log P,,, values. 
Approximate estimated standard errors are shown in 
parentheses beneath each best-fit parameter value. The 
best fit is obtained for n = 4 
bezafibrate concentrations on the P,,, for hemo- 
globin solutions when the two effecters are present 
in the same solution. From a single measured curve 
in the presence of 5 mM bezafibrate and 10 mM 
DPG and some preliminary crystallographic data, 
authors in [l] inferred different binding sites for 
the two effecters and a resulting synergy of effect. 
A more rigorous analysis is possible with the pre- 
sent data. If the two compounds bind at the same 
site, such that the binding of one excludes the 
other, then the equation corresponding to eq.1 is 
(where subscript 1 refers to DPG and 2 to bezafi- 
brate and Alog Pm is the difference between treated 
and control curves): 
Alog P,,, = $ log d&u, + (1 + &&2)4 
d&o1 + (I + dzKo,)4 
(2) 
If the compounds bind at completely different 
sites then the appropriate equation is: 
1 
‘log pm = i log 
(1 + d&D& 1 + dz&)4 
(1 + diKoi)(l + dzKozj4 1 (3) 
A third situation may be identified, one of mix- 
ed competition where 2 of the 4 sites for 
bezafibrate are competitive with DPG binding and 
Table 2 
Observed and calculated log P,,, values for DPG and 
bezafibrate in combination 
DPG 
cont. 
MW 
Beza- Observed 
fibrate log P,,, 
cont. 
(mM) 
Calculated log P,,, 
eq.2 eq.3 eq.4 
1 1 1.25 1.19 1.33 1.26 
1 2 1.32 1.20 1.44 1.31 
1 5 1.41 1.29 1.65 1.42 
1 10 1.57 1.46 1.84 1.54 
2 1 1.30 1.25 1.40 1.32 
2 2 1.36 1.26 1.51 1.38 
2 5 1.46 1.31 1.71 1.48 
2 10 1.59 1.46 1.90 1.58 
5 1 1.39 1.32 1.48 1.40 
5 2 1.47 1.32 1.58 1.45 
5 5 1.56 1.35 1.79 1.55 
5 10 1.64 1.46 1.98 1.64 
Residual sum 
of squares: 0.200 0.531 0.003 
The log Pm values were determined as described in the 
text for the DPG and bezafibrate concentrations 
indicated. The calculated values were obtained using 
eq.2 (competitive), eq.3 (non-competitive) and eq.4 
(mixed competition) with KD and KO values of 3.53 x 
104 and 87.8 mol-’ for DPG and 434 and 19.0 mol-’ for 
bezafibrate. The log Pm for stripped hemoglobin was 
0.81. The residual sum of squares between observed and 
calculated log Pm values show that eq.4 representing 2 
sites competitive with DPG binding and 2 non- 
competitive, gives the best fit to the data 
2 are remote from the DPG site. The appropriate 
equation is then: 
Alog Pm = 
The KD and KO values for bezafibrate and DPG 
obtained from fitting eq.1 to the data for these 
compounds alone, may be substituted into eq.2-4 
to calculate the expected log P,,, values for these 
alternative binding situations. It is clear that the 
mixed competitive model of eq.4 gives the closest 
agreement between observed and calculated log P,,, 
values and this is emphasized by the last figure in 
each column for the sum of squares of residuals 
between observed and calculated values. The data 
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therefore indicate only partial synergy of effects 
for DPG and bezafibrate with 2 of the 4 binding 
sites competitive with DPG binding and two 
remote from the DPG binding site. 
4. DISCUSSION 
Most right-shifting compounds so far described 
are highly charged anionic compounds and bind at 
a single site, the DPG binding site, in deox- 
yhemoglobin [4,6-g]. Recently, however, anionic 
compounds which also possess a hydrophobic 
component have been shown to bind at more than 
one site. &Naphthyl triphosphate was reported to 
bind in a 2: 1 molar ratio [lo] and the dye, 
erythrosin, was observed to bind to a large number 
of binding sites in both deoxy- and ox- 
yhemoglobin, but with 4 molecules bound more 
strongly than the rest [ll]. In addition it was 
shown [lo] that one of the fl-naphthyl triphosphate 
binding sites is competitive with DPG binding and 
2 of the 4 strong erythrosin binding sites are com- 
petitive with IHP (and thus DPG) binding [12]. 
The steep slope of the log P, vs log-dose curve 
for the hydrophobic anion bezafibrate clearly 
demonstrates multiple sites for the binding of the 
compound to deoxyhemoglobin and 4 sites gave 
the best fit to the data. The site binding constant 
of 434 mol-’ represents weak binding compared 
with DPG (3.53 x lo4 mol-’ under the same condi- 
tions) and the data give no information on any 
further binding which is not oxygen-linked, as 
observed for erythrosin. In fact, clofibrate, an 
analogue of bezafibrate was reported to have up to 
12 binding sites to deoxyhemoglobin [13]. 
However, any such additional binding would not 
significantly affect the results of the present 
analysis due to the high compound to hemoglobin 
ratios employed. 
The combination experiments with DPG in- 
dicate competition for binding at 2 of the 4 
bezafibrate binding sites. The binding site for DPG 
at the P-terminal amino region is highly positively 
charged but there are extensive hydrophobic areas 
on each side of this region. Modelling indicates 
that there is room for two molecules of bezafibrate 
to bind in an antiparallel fashion with their charg- 
ed ends interacting with the terminal amino groups 
themselves and/or adjacent histidine residues u2 
and ,&143) and the hydrophobic ends extending in- 
190 
to the hydrophobic areas particularly near residues 
Leu-8lP, Phe-85@ and Val-137P. The identity of 
the remaining two oxygen-linked sites is less clear, 
although the binding of inorganic anions [14] and 
certain pyridoxal derivatives [15-171 at the (Y- 
terminal amino region suggests this as a likely can- 
didate. Again two possible binding sites may be 
identified comprising the terminal amino groups 
of one a-chain and arginine 141 of the other for 
the ionic component and residues Trp-37fl, 
Pro-95a and Tyr-14Oo as part of a hydrophobic 
component. Crystallographic data for clofibrate 
[ 131 revealed only binding in the center of the 
hemoglobin tetramer and this was also indicated 
for bezafibrate [I]. However, the crystallizations 
were performed under conditions of high salt con- 
centration which would inhibit the ionic binding at 
the a- and &terminal amino regions and favour 
purely hydrophobic bonding as observed. 
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